XNCR Xencor, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

XNCR [NASD]

Xencor, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.08	Insider Own	0.60%	Shs Outstand	56.95M	Perf Week	-2.89%
Market Cap	1.82B	Forward P/E	-	EPS next Y	-1.28	Insider Trans	-67.81%	Shs Float	55.84M	Perf Month	5.88%
Income	-61.20M	PEG	-	EPS next Q	-0.48	Inst Own	96.60%	Short Float	6.87%	Perf Quarter	3.34%
Sales	77.10M	P/S	23.62	EPS this Y	135.20%	Inst Trans	3.67%	Short Ratio	6.98	Perf Half Y	-8.05%
Book/sh	10.41	P/B	3.06	EPS next Y	14.10%	ROA	-9.00%	Target Price	44.17	Perf Year	-27.45%
Cash/sh	10.04	P/C	3.17	EPS next 5Y	-	ROE	-10.20%	52W Range	19.35 - 46.33	Perf YTD	-7.33%
Dividend	-	P/FCF	21.79	EPS past 5Y	23.50%	ROI	2.30%	52W High	-31.21%	Beta	1.05
Dividend %	-	Quick Ratio	8.90	Sales past 5Y	75.10%	Gross Margin	-	52W Low	64.70%	ATR	1.56
Employees	166	Current Ratio	8.90	Sales Q/Q	-71.00%	Oper. Margin	-94.80%	RSI (14)	49.13	Volatility	3.61% 5.35%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-110.30%	Profit Margin	-79.40%	Rel Volume	0.36	Prev Close	31.95
Shortable	No	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	549.64K	Price	31.87
Recom	2.00	SMA20	0.85%	SMA50	2.00%	SMA200	-4.73%	Volume	196,351	Change	-0.25%

Mar-04-20

Initiated

Barclays

Underweight

$28

Feb-25-20

Upgrade

Guggenheim

Neutral → Buy

$43

Jan-30-20

Initiated

RBC Capital Mkts

Outperform

$44

Nov-20-19

Resumed

Guggenheim

Neutral

Aug-07-19

Downgrade

Raymond James

Outperform → Mkt Perform

Aug-07-19

Downgrade

Guggenheim

Buy → Neutral

Jun-13-19

Initiated

Mizuho

Buy

Apr-12-19

Initiated

Guggenheim

Buy

Mar-27-19

Initiated

Berenberg

Buy

$45

Mar-15-19

Initiated

Raymond James

Outperform

Sep-10-18

Resumed

BTIG Research

Buy

$56

Mar-28-18

Resumed

Leerink Partners

Outperform

$36

Mar-02-17

Reiterated

Wedbush

Outperform

$27 → $33

Mar-02-17

Initiated

Instinet

Neutral

$21

Oct-04-16

Initiated

Piper Jaffray

Overweight

Dec-22-15

Initiated

Canaccord Genuity

Buy

$20

Aug-05-15

Reiterated

MLV & Co

Buy

$22 → $29

Feb-12-15

Reiterated

Oppenheimer

Outperform

$22 → $28

Jan-28-15

Reiterated

MLV & Co

Buy

$18 → $22

Jul-11-14

Initiated

Oppenheimer

Outperform

$22

Jul-08-20 08:01AM	Atreca and Xencor Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies GlobeNewswire
08:01AM	Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies Business Wire
Jun-30-20 11:35PM	Were Hedge Funds Right About Selling Xencor Inc (XNCR)? Insider Monkey
Jun-22-20 09:06AM	Xencor Presents Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II Business Wire +6.57%
Jun-08-20 01:48PM	Edited Transcript of XNCR earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents +6.22%
May-26-20 04:01PM	Xencor to Present at Upcoming Investor Conferences Business Wire
May-15-20 12:01AM	Xencor to Present Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II Business Wire
May-13-20 05:00PM	Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors Business Wire
09:01AM	Xencor to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference Business Wire
May-11-20 01:35PM	Growth Investors: Industry Analysts Just Upgraded Their Xencor, Inc. (NASDAQ:XNCR) Revenue Forecasts By 22% Simply Wall St.
May-08-20 09:30PM	Xencor Inc (XNCR) Q1 2020 Earnings Call Transcript Motley Fool +10.30%
May-07-20 04:01PM	Xencor Reports First Quarter 2020 Financial Results Business Wire
Apr-30-20 04:01PM	Xencor to Host First Quarter 2020 Financial Results Webcast and Conference Call on May 7, 2020 Business Wire -6.34%
Apr-13-20 03:49PM	Introducing Xencor (NASDAQ:XNCR), The Stock That Zoomed 109% In The Last Five Years Simply Wall St.
Apr-07-20 02:10PM	Hedge Funds Are Buying Xencor Inc (XNCR) Insider Monkey -10.95%
Mar-26-20 08:23AM	The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan Merger Benzinga +5.28%
Mar-25-20 04:01PM	Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend XmAb® Antibody Technology in Investigational Antibodies to Treat COVID-19 Business Wire
Mar-02-20 02:55PM	MorphoSys BLA for Cancer Drug Gets Priority Review from FDA Zacks
Feb-28-20 07:43AM	Edited Transcript of XNCR earnings conference call or presentation 24-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Feb-26-20 11:59AM	How Should Investors Feel About Xencor, Inc.'s (NASDAQ:XNCR) CEO Pay? Simply Wall St.
Feb-24-20 05:45PM	Xencor (XNCR) Reports Q4 Loss, Lags Revenue Estimates Zacks -5.26%
04:01PM	Xencor Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire
Feb-18-20 08:01AM	Xencor to Host Fourth Quarter and Full Year 2019 Financial Results Webcast and Conference Call on February 24, 2020 Business Wire
Feb-17-20 12:30PM	Earnings Preview: Xencor (XNCR) Q4 Earnings Expected to Decline Zacks
Feb-06-20 04:01PM	Xencor to Present at Upcoming Investor Conferences Business Wire
Feb-05-20 10:28AM	After peanut allergy drug approval, Peninsula biotech munches sweet $200M deal American City Business Journals +5.61%
08:01AM	Aimmune Licenses Exclusive Worldwide Rights to Xencors XmAb®7195 for the Development of Next-Generation Food Allergy Treatments Business Wire
Jan-09-20 05:10PM	Gilead (GILD) Inks License Deal with Xencor for HIV Candidate Zacks -5.17%
Jan-08-20 12:08PM	How Xencor, Inc. (NASDAQ:XNCR) Can Impact Your Portfolio Volatility Simply Wall St.
08:01AM	Xencor and Gilead Enter License Agreement for Use of XmAb® Antibody Technologies in Investigational Agents for HIV Business Wire
Dec-30-19 10:13AM	Company News For Dec 30, 2019 Zacks
Dec-20-19 08:01AM	Xencor Appoints Dagmar Rosa-Bjorkeson to Board of Directors Business Wire
Dec-18-19 08:01AM	Xencor Appoints Allen Yang, M.D., Ph.D., as Senior Vice President and Chief Medical Officer Business Wire
Dec-14-19 08:05PM	Here is What Hedge Funds Think About Xencor Inc (XNCR) Insider Monkey
Dec-09-19 10:00AM	Xencor Presents Initial Data from Phase 1 Study of XmAb®13676 in B-cell Malignancies at the ASH Annual Meeting Business Wire
Nov-19-19 12:58PM	Is Xencor, Inc. (NASDAQ:XNCR) Trading At A 44% Discount? Simply Wall St.
10:33AM	Drug Legislation Likely to Dry Up Biotech Funding GuruFocus.com
Nov-18-19 11:48PM	Edited Transcript of XNCR earnings conference call or presentation 5-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-13-19 04:01PM	Xencor to Present at Upcoming Investor Conferences Business Wire
Nov-06-19 09:00AM	Xencor to Present Initial Data from the Phase 1 Study of XmAb®13676 in B-Cell Malignancies at the American Society of Hematology Annual Meeting Business Wire
Nov-05-19 06:05PM	Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM	Xencor Reports Third Quarter 2019 Financial Results Business Wire
Oct-29-19 04:01PM	Xencor to Host Third Quarter 2019 Financial Results Webcast and Conference Call on November 5, 2019 Business Wire
Oct-28-19 10:31AM	Earnings Preview: Xencor (XNCR) Q3 Earnings Expected to Decline Zacks
Oct-21-19 12:55PM	Hedge Funds Are Selling Xencor Inc (XNCR) Insider Monkey
Oct-10-19 03:34PM	Can Xencor, Inc. (NASDAQ:XNCR) Improve Its Returns? Simply Wall St.
Sep-26-19 04:01PM	Xencor to Present at the 2019 Cantor Global Healthcare Conference Business Wire
Sep-10-19 04:01PM	Xencor Appoints Celia Eckert as Vice President, General Counsel and Corporate Secretary Business Wire
Aug-23-19 10:00AM	Is Xencor's (NASDAQ:XNCR) 263% Share Price Increase Well Justified? Simply Wall St. -5.65%
Aug-22-19 09:15PM	Xencor Inc (XNCR) Sr. Vice President & CFO John J Kuch Sold $1.7 million of Shares GuruFocus.com -6.08%
Aug-21-19 06:53AM	Edited Transcript of XNCR earnings conference call or presentation 6-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-19 11:13AM	Xencor Inc (XNCR) Q2 2019 Earnings Call Transcript Motley Fool
Aug-06-19 06:05PM	Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM	Xencor Reports Second Quarter 2019 Financial Results Business Wire
Aug-01-19 04:01PM	Xencor to Present at Upcoming Investor Conferences Business Wire
Jul-30-19 04:01PM	Xencor to Host Second Quarter 2019 Financial Results Webcast and Conference Call on August 6, 2019 Business Wire
Jul-12-19 06:16PM	Edited Transcript of XNCR earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
Jul-09-19 12:52PM	What You Must Know About Xencor, Inc.'s (NASDAQ:XNCR) Financial Health Simply Wall St.
Jul-02-19 08:58AM	Xencor (XNCR) Jumps: Stock Rises 7.4% Zacks
Jun-27-19 08:01AM	Xencor Announces the Planned Retirement of Chief Medical Officer Paul Foster, M.D. Business Wire
Jun-26-19 10:12AM	Company News For Jun 26, 2019 Zacks
Jun-24-19 06:00PM	MarketAxess Holdings Set to Join S&P 500; Axon Enterprise to Join S&P MidCap 400; Others to Join S&P SmallCap 600 PR Newswire
01:38PM	Heres What Hedge Funds Think About Xencor Inc (XNCR) Insider Monkey
Jun-08-19 09:14AM	One Thing To Remember About The Xencor, Inc. (NASDAQ:XNCR) Share Price Simply Wall St.
Jun-03-19 08:01AM	Xencor Doses First Patient in Phase 1 Study of XmAb®22841 for the Treatment of Patients with Advanced Solid Tumors Business Wire
May-23-19 08:01AM	Xencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development Business Wire
May-10-19 09:23AM	Xencor Inc (XNCR) Q1 2019 Earnings Call Transcript Motley Fool +10.31%
May-09-19 04:43PM	Xencor: 1Q Earnings Snapshot Associated Press
04:00PM	Xencor Reports First Quarter 2019 Financial Results Business Wire
May-08-19 04:01PM	Xencor to Present at Upcoming Investor Conferences Business Wire
May-06-19 08:01AM	Xencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors Business Wire
May-02-19 04:01PM	Xencor to Host First Quarter 2019 Financial Results Webcast and Conference Call on May 9, 2019 Business Wire
May-01-19 01:22PM	Is Xencor, Inc. (NASDAQ:XNCR) Trading At A 24% Discount? Simply Wall St.
Apr-30-19 08:01AM	Xencor Announces Partial Clinical Hold Lifted on Phase 1 Study of XmAb®14045 Business Wire
Apr-29-19 09:55PM	Heres What Hedge Funds Think About Xencor Inc (XNCR) Insider Monkey
Apr-02-19 08:01AM	Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program Business Wire
Apr-01-19 04:05PM	Xencor to Participate in Upcoming Investor Conferences Business Wire
12:55PM	Why I Like Xencor, Inc. (NASDAQ:XNCR) Simply Wall St.
Mar-08-19 08:01AM	Xencor Announces Closing of Research Collaboration and License Agreement with Genentech Business Wire
Mar-06-19 07:00AM	New Research Coverage Highlights Clovis Oncology, Welltower, The Ultimate Software Group, Nielsen Holdings Plc, Xencor, and 21Vianet Group Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Mar-01-19 12:30PM	Is Xencor, Inc.s (NASDAQ:XNCR) CEO Paid Enough Relative To Peers? Simply Wall St.
06:18AM	Edited Transcript of XNCR earnings conference call or presentation 25-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Feb-28-19 09:15AM	Too Much Talking, Not Enough Action Zacks
Feb-26-19 09:48PM	Xencor Inc (XNCR) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
09:11AM	Nielsen (NLSN) to Report Q4 Earnings: What's in the Offing? Zacks
Feb-25-19 09:05PM	Xencor Inc (XNCR) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:24PM	Xencor Reports Fourth Quarter and Full Year 2018 Financial Results PR Newswire
02:30PM	Xencor, Inc. to Host Earnings Call ACCESSWIRE
09:12AM	What's in Store for Booking Holdings' (BKNG) Q4 Earnings? Zacks
Feb-23-19 09:15AM	Strong Friday Close Secures a 9th Week in the Green Zacks
Feb-20-19 06:55AM	Xencor Announces Partial Clinical Hold on Phase 1 Study of XmAb14045 PR Newswire -6.54%
Feb-19-19 09:01AM	Xencor to Host Fourth Quarter and Full Year 2018 Financial Results Webcast and Conference Call on February 25, 2019 PR Newswire
Feb-07-19 09:01AM	Xencor to Present at Upcoming Investor Conferences PR Newswire
Feb-05-19 08:01AM	Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech PR Newswire
Jan-28-19 07:35AM	Report: Developing Opportunities within ONEOK, Alaska Air Group, Comcast, Mack-Cali Realty, Vistra Energy, and Xencor Future Expectations, Projections Moving into 2019 GlobeNewswire
Jan-21-19 06:12AM	Have Insiders Been Selling Xencor, Inc. (NASDAQ:XNCR) Shares This Year? Simply Wall St.
Jan-07-19 08:01AM	Xencor Regains ex-U.S. Commercial Rights to XmAb®13676, CD20 x CD3 Bispecific Antibody PR Newswire
Dec-06-18 10:45AM	Is Xencor Inc (NASDAQ:XNCR) A Financially Strong Company? Simply Wall St.
Dec-04-18 07:35AM	Consolidated Research: 2018 Summary Expectations for Xencor, Cyclacel Pharmaceuticals, Amicus Therapeutics, Take-Two Interactive Software, CSG Systems International, and Vonage Fundamental Analysis, Key Performance Indications GlobeNewswire -6.28%
Dec-03-18 05:45PM	Xencor Presents Initial Data from Phase 1 Study of XmAb®14045 in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting PR Newswire

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat cancer and autoimmune diseases. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; AIMab7195, which is in development and commercialization stage. Its product candidates also comprise XmAb14045, a bispecific antibody which is in Phase I clinical trial for the treatment of acute myeloid leukemia; plamotamab (XmAb13676) that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers Tafasitamab, an antibody drug candidate for the treatment of patients with relapsed/refractory diffuse; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG509, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104 which are in preclinical Phase. Additionally, it offers XmAb24306, initial cytokine candidate which is in Phase I clinical trial. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; MorphoSys Ag; Amgen Inc.; and Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kuch John J	Sr. Vice President & CFO	Jun 12	Option Exercise	11.05	10,000	110,500	90,602	Jun 16 08:45 PM
STAFFORD JOHN S III	10% Owner	Apr 06	Sale	27.43	644,771	17,685,509	606,005	Apr 08 04:26 PM
Ronin Capital, LLC	10% Owner	Mar 20	Sale	29.89	50,770	1,517,642	5,012,430	Mar 23 05:37 PM
Ronin Capital, LLC	10% Owner	Mar 19	Sale	28.23	26,800	756,593	5,063,200	Mar 23 05:37 PM
STAFFORD JOHN S III	10% Owner	Jan 08	Sale	36.68	60,876	2,232,932	1,250,776	Jan 08 05:28 PM
STAFFORD JOHN S III	10% Owner	Jan 07	Sale	35.95	6,047	217,390	1,311,652	Jan 08 05:28 PM
STAFFORD JOHN S III	10% Owner	Jan 06	Sale	35.81	58,862	2,107,907	1,317,699	Jan 08 05:28 PM
STAFFORD JOHN S III	10% Owner	Dec 26	Sale	40.04	4,119	164,925	1,376,561	Dec 26 05:07 PM
STAFFORD JOHN S III	10% Owner	Dec 24	Sale	39.71	43,720	1,736,121	1,380,680	Dec 26 05:07 PM
STAFFORD JOHN S III	10% Owner	Dec 23	Sale	39.51	91,677	3,622,342	1,424,400	Dec 26 05:07 PM
STAFFORD JOHN S III	10% Owner	Dec 20	Sale	39.39	73,423	2,892,132	1,516,077	Dec 26 05:07 PM
STAFFORD JOHN S III	10% Owner	Dec 11	Sale	38.68	37,951	1,467,945	1,589,500	Dec 11 06:48 PM
STAFFORD JOHN S III	10% Owner	Dec 10	Sale	40.13	252,225	10,121,789	1,627,451	Dec 11 06:48 PM
STAFFORD JOHN S III	10% Owner	Dec 09	Sale	41.64	120,324	5,009,750	1,879,676	Dec 11 06:48 PM
Desjarlais John R	Sr. V.P., Research & CSO	Sep 06	Option Exercise	4.25	27,522	116,969	83,868	Sep 10 06:12 PM
Kuch John J	Sr. Vice President & CFO	Aug 21	Option Exercise	11.05	20,000	221,000	113,629	Aug 22 07:59 PM
Kuch John J	Sr. Vice President & CFO	Aug 21	Sale	41.27	40,000	1,650,724	73,629	Aug 22 07:59 PM
Desjarlais John R	Sr. V.P., Research & CSO	Aug 19	Sale	40.69	35,000	1,424,150	56,346	Aug 21 04:21 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience